Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab for Primary Refractory or Early Relapsed DLBCL (Real-World Study)
ChiCTR2600122028Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600122028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122028.